SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status:
Completed
Trial end date:
2013-09-20
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to demonstrate the efficacy of SPD489 compared with
placebo in adults (18 55 years of age inclusive) with moderate to severe Binge Eating
Disorder at Visit 8 (Weeks 11 and 12) as measured by the number of binge days (defined as
days during which at least 1 binge episode occurs) per week as assessed by clinical interview
based on subject diary